Thermo Fisher Scientific reported second-quarter 2026 revenue of $11.99 billion, up 10% year over year, and adjusted earnings per share of $6.03, up 13%, according to the company’s press release issued 23 July. Organic revenue growth was 5%. GAAP diluted EPS was $4.68, up 9%.
Analytical Instruments carries the margin story
The Analytical Instruments segment posted revenue of $1.847 billion, up 6.9% from $1.728 billion a year earlier and up 7% organically. Segment income rose to $424 million from $325 million, and adjusted operating margin expanded 420 basis points to 23.0% from 18.8% a year earlier - the largest year-over-year margin move among the company’s four reporting segments this quarter.
On the earnings call, chief executive Marc Casper attributed the segment’s growth to new product launches, adoption of high-end instrumentation in the academic sector, and the reception of AI-enabled software features tied to recent mass spectrometry releases. He described China as returning to growth but still uneven across end markets.
Guidance lifted
Management raised full-year 2026 guidance during the call to a revenue range of $47.4 billion to $48.1 billion, and an adjusted EPS range of $24.93 to $25.33, implying 9% to 11% adjusted EPS growth for the year. The prior guide, issued alongside first-quarter results, sat below both figures.
Context for operators and the peer set
The 23.0% adjusted operating margin in Analytical Instruments is the segment’s highest print in the last several quarters and lifts Thermo Fisher’s Q2 performance well above the flat Q1 read Spectrane covered in April (see the Q1 2026 analytical-instruments recap). For the peer set, it lands between Bruker’s Q1 organic dip and Mettler-Toledo’s Q1 process-analytics read, and reinforces the broader picture across analytical-instruments capex through 2026: academic and high-end demand is holding, and the pricing environment is still favourable to vendors carrying differentiated instrumentation.